Founded and led by rare disease veterans, Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments. Palvella's development model involves partnering with patient advocacy organizations and their patient registries to design fit-for-purpose, accelerated clinical development programs aimed at expediting the introduction of targeted therapies to patients who currently lack any approved treatment options. Palvella's lead program, PTX-022 (QTORIN™ 3.9% rapamycin anhydrous gel), is in a Phase 2/3 pivotal study for pachyonychia congenita (PC), a rare, chronically debilitating and lifelong genetic disease estimated to affect more than 9,000 individuals in the U.S.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/30/20 | $45,000,000 | Series C |
Adams Street Partners Agent Capital BioAdvance BVF Partners CAM Capital Ligand Pharmaceuticals Nolan Capital Opaleye Management Samsara BioCapital | undisclosed |
